ABL Bio to Attend JPM Healthcare Conference 2026

ABL Bio, a company specializing in bispecific antibodies, announced on January 2 that it will attend the 44th JPM Healthcare Conference 2026, which will be held in San Francisco, California, USA, from January 12 to 15, to explore various partnership opportunities.

The JPM Healthcare Conference is the largest and most influential healthcare investment event in the world. It is attended by a wide range of participants, including domestic and international pharmaceutical and biotech companies, investors, scientists, and developers. Since its founding, ABL Bio has been invited to and participated in this conference every year.

At this event, ABL Bio plans to hold follow-up and new meetings with global pharmaceutical and biotech companies with whom it has been discussing partnerships. The company will also meet with investors interested in NEOK Bio to discuss future development strategies. NEOK Bio is an independent entity established by ABL Bio in the United States, responsible for the clinical development of bispecific antibody ADCs ABL206 (NEOK001) and ABL209 (NEOK002).

In particular, the technology attracting the most interest from global pharmaceutical and biotech companies at this meeting is the blood-brain barrier (BBB) shuttle platform, Grabody-B. In April of last year, ABL Bio signed a technology transfer agreement for Grabody-B with global pharmaceutical company GSK, valued at 2.1401 billion pounds (approximately 4.1 trillion won). In November of the same year, the company also entered into a technology transfer agreement for Grabody with Eli Lilly, valued at 2.602 billion dollars (approximately 3.8 trillion won), along with a strategic equity investment agreement worth 15 million dollars (approximately 22 billion won), drawing significant attention.

ABL Bio also plans to continue sharing clinical data on immuno-oncology drugs utilizing its 4-1BB-based bispecific antibody platform, Grabody-T. Recently, one of the Grabody-T-based pipeline candidates, ABL503 (Ragistomig), achieved encouraging results in a Phase 1 clinical trial, where the dosing interval was adjusted from every two weeks to every six weeks, demonstrating anti-tumor activity suitable for combination therapy and excellent safety data. Another Grabody-T-based pipeline, ABL111 (Givastomig), is also scheduled to release additional Phase 1b clinical data on combination therapy with chemotherapy and Nivolumab in the first half of this year.

Lee Sanghoon, CEO of ABL Bio, stated, "With our participation in the JP Morgan Healthcare Conference, we are officially kicking off 2026. This year will be an extremely important one for ABL Bio. The results of the Phase 2/3 clinical trial for ABL001, which is being developed as a second-line treatment for cholangiocarcinoma, are expected to be announced in the first half of this year. The announcement was delayed as the mortality rate among clinical trial participants was lower than initially expected, so we are hopeful for positive outcomes. We also plan to initiate a Phase 1 clinical trial for bispecific antibody ADCs this year, and to announce Phase 1b data for ABL111. We ask for your continued support and interest in ABL Bio throughout the year."